Is the Toxicity of Salvage Prostatectomy Related to the Primary Prostate Cancer Therapy Received?


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
03 2021
Historique:
pubmed: 7 10 2020
medline: 15 4 2021
entrez: 6 10 2020
Statut: ppublish

Résumé

To compare the toxicity profile and oncological outcome of salvage radical prostatectomy following focal therapy versus salvage radical prostatectomy after radiation therapies (external beam radiation therapy or brachytherapy). Data concerning all men undergoing salvage radical prostatectomy for recurrent prostate cancer after either focal therapy, external beam radiation therapy or brachytherapy were retrospectively collected from 4 high volume surgical centers. The primary outcome measure of the study was toxicity of salvage radical prostatectomy characterized by any 30-day postoperative Clavien-Dindo complication rate, 12-month continence rate and 12-month potency rate. The secondary outcome was oncological outcome after salvage radical prostatectomy including positive margin rate and 12-month biochemical recurrence rate. Biochemical recurrence was estimated using Kaplan-Meier methods and significant differences were calculated using a log rank test. Median followup was 29.5 months. Between April 2007 and September 2018, 185 patients underwent salvage radical prostatectomy of whom 95 had salvage radical prostatectomy after focal therapy and 90 had salvage radical prostatectomy after radiation therapy (external beam radiation therapy or brachytherapy). Salvage radical prostatectomy after radiation therapy was associated with a significantly higher 30-day Clavien-Dindo I-IV complication rate (34% vs 5%, p <0.001). At 12 months following surgery, patients undergoing salvage radical prostatectomy after focal therapy had significantly better continence (83% pad-free vs 49%) while potency outcomes were similar (14% vs 11%). Men undergoing salvage radical prostatectomy after radiation therapy had a significantly higher stage and grade of disease together with a higher positive surgical margin rate (37% vs 13%, p=0.001). The 3-year biochemical recurrence after focal therapy was 35% compared to 32% after radiation therapy (p=0.76). In multivariable analysis, men undergoing salvage radical prostatectomy after focal therapy experienced a higher risk of biochemical recurrence (HR 0.36, 95% CI 0.16-0.82, p=0.02). This multicenter study demonstrates the toxicity of salvage radical prostatectomy in terms of perioperative complications and long-term urinary continence recovery is dependent on initial primary prostate cancer therapy received with men undergoing salvage radical prostatectomy after focal therapy experiencing lower postoperative complication rates and better urinary continence outcomes.

Identifiants

pubmed: 33021441
doi: 10.1097/JU.0000000000001382
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

791-799

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Auteurs

Luis Ribeiro (L)

Urology Centre, Guys and St Thomas NHS Trust, London, United Kingdom.

Thomas Stonier (T)

Department of Urology, Kings College Hospital, London, United Kingdom.

Luke Stroman (L)

Urology Centre, Guys and St Thomas NHS Trust, London, United Kingdom.

Rafael Tourinho-Barbosa (R)

Deptartment of Urology, Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Omar Alghazo (O)

Division of Cancer Surgery, Sir Peter MacCallum Cancer Centre, Melbourne, Australia.

Mathias Winkler (M)

Imperial College NHS Foundation Trust, London, United Kingdom.

Prokar Dasgupta (P)

Urology Centre, Guys and St Thomas NHS Trust, London, United Kingdom.

Rick Popert (R)

Urology Centre, Guys and St Thomas NHS Trust, London, United Kingdom.

Xavier Cathelineau (X)

Deptartment of Urology, Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Rafael Sanchez-Salas (R)

Deptartment of Urology, Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Declan G Murphy (DG)

Division of Cancer Surgery, Sir Peter MacCallum Cancer Centre, Melbourne, Australia.

Mark Emberton (M)

University College London Hospitals NHS Trust, London, United Kingdom.

Paul Cathcart (P)

Urology Centre, Guys and St Thomas NHS Trust, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH